RIPK1 and amyotrophic lateral sclerosis: It is suggested that therapeutic strategies aiming to reduce ROS levels and RIPK1 activity, as well as to recover TDP-43 homeostasis, could be useful for ALS patients carrying a dysfunctional TBK1 protein.